hotspot -WSS

hotspot

author：knowledge 2025-08-25 08:45:22 - browse：6145

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Ancient Greek ideas underpin modern concepts of pregnancy

WSS

The untold story of TV’s first prescription drug ad

Transgender sports debate: Physicians say bans are health issue

FDA panel to weigh safety of artificial wombs for preterm births

Streamlined flu vaccines recommended by FDA advisory panel

Why the drug industry's warnings on the IRA's impact fall short

Florida health officials providing scant details on measles cases

explore

hotspot

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Change Healthcare: What is it, why does its cyberattack matter?

What does generative AI mean for health care? We asked experts

Streamlined flu vaccines recommended by FDA advisory panel

Guidelines to prevent youth baseball injuries need more muscle

Ozempic has benefits for kidney disease as well as diabetes

Novavax promises a turnaround & Lilly roils the obesity market

The public health thinking behind the CDC’s new Covid guidance

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: BridgeBio, Akero, and human embryo models

leisure time

Ozempic has benefits for kidney disease as well as diabetes

IVF doctors demand details after CooperSurgical lawsuit

Medicare drug price negotiation continues, as pharma counteroffers

Longer MASH drug regimen improved liver, Akero study finds

Florida health officials providing scant details on measles cases

House panel takes first step toward fixing drug shortages

hotspot

focus

explore

Wikipedia